CA
NZ
UK
AU
IND
US
• Quanterix is up 2.12% intraday at $3.86 with above-average volume, suggesting the Bio-Techne M&A catalyst is generating genuine interest rather than passive drift.
• Repligen is up 5.38% intraday at $145.84, holding near session highs on above-average volume, a technically constructive sign of sustained institutional buying.
• Veradermics is down a fractional 0.22% intraday at $117.03, effectively unchanged with very light volume and no new company-specific announcement.
• Meritage Homes is up 1.12% intraday at $83.31, with a more muted gain than deeply discounted peers, reflecting a mid-52-week-range position and moderate housing recovery ambivalence.
• IceCure Medical is down 20.43% intraday at $7.40 with heavy selling from the open and no meaningful recovery bounce, suggesting simultaneous exit by weaker holders.
• ICON plc is up 5.11% intraday at $166.26, having risen from near $138 in early June, with dip buyers consistently active on any weakness signalling strong institutional conviction.
• InMode is up approximately 11% intraday at $14.83 after receiving a take-private proposal at $16.20 per share from M.N. Business Strategy, which includes co-founder and CEO Moshe Mizrahy.
• Medpace Holdings is up 2.62% intraday at $526.21, with the gain measured and steady, consistent with institutional CRO sector positioning.
• Monopar Therapeutics is up 2.47% intraday at $91.19 with the gain steady and without violent spikes, suggesting low-level accumulation rather than speculative momentum chasing.
• Myriad Genetics is up 4.60% intraday at $5.46 with the gain sustained through the session, suggesting the M&A re-rating is doing genuine work rather than producing a fleeting spike.
Please wait processing your request...